Reviewing Actinium Pharmaceuticals (ATNM) & Its Rivals

Actinium Pharmaceuticals (NYSE:ATNM) is one of 1,030 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Actinium Pharmaceuticals to related businesses based on the strength of its earnings, analyst recommendations, institutional ownership, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares Actinium Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Actinium Pharmaceuticals	$80,000.00	-$48.82 million	-1.05
Actinium Pharmaceuticals Competitors	$2.12 billion	$148.62 million	-4.64

Actinium Pharmaceuticals’ rivals have higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Actinium Pharmaceuticals has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals’ rivals have a beta of 1.01, indicating that their average share price is 1% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Actinium Pharmaceuticals and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	1	4	0	2.80
Actinium Pharmaceuticals Competitors	7209	20137	47054	1104	2.56

Actinium Pharmaceuticals currently has a consensus price target of $11.40, indicating a potential upside of 536.87%. As a group, “Pharmaceutical preparations” companies have a potential upside of 62.29%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Actinium Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-101.69%	-48.91%
Actinium Pharmaceuticals Competitors	-3,628.10%	-299.05%	-32.34%

Institutional & Insider Ownership

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Actinium Pharmaceuticals rivals beat Actinium Pharmaceuticals on 7 of the 13 factors compared.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.